BioLine Rx (XTAE:BLRX) Price-to-Operating-Cash-Flow : (As of May. 01, 2024)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Price-to-Operating-Cash-Flow?

As of today (2024-05-01), BioLine Rx's share price is ₪0.176. BioLine Rx's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-0.09. Hence, BioLine Rx's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for BioLine Rx's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, BioLine Rx's highest Price-to-Operating-Cash-Flow Ratio was 6.52. The lowest was 0.00. And the median was 5.98.

XTAE:BLRX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 26.12
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

BioLine Rx's Cash Flow from Operations per share for the three months ended in Dec. 2023 was ₪0.02. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-0.09.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 36.50% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 38.10% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 28.80% per year.

During the past 13 years, BioLine Rx's highest 3-Year average Operating Cash Flow per Share Growth Rate was 45.80% per year. The lowest was 6.80% per year. And the median was 29.70% per year.

BioLine Rx Price-to-Operating-Cash-Flow Historical Data

The historical data trend for BioLine Rx's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Price-to-Operating-Cash-Flow Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioLine Rx's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, BioLine Rx's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Price-to-Operating-Cash-Flow falls into.

BioLine Rx Price-to-Operating-Cash-Flow Calculation

BioLine Rx's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.176	/	-0.094
	=

BioLine Rx's Share Price of today is ₪0.176.
BioLine Rx's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-0.09.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

BioLine Rx Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.